Nevada Board of Pharmacy posted notice of hearing on proposed amendment to add dipentylone and seven fentanyl-related substances to Schedule I (NAC 453.510)

The Nevada State Board of Pharmacy issued a public hearing notice for LCB File No. R107-25 proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, described as being in conformity with federal regulations. The notice sets a public hearing date of March 5, 2026. If adopted, these additions would expand Nevada’s Schedule I list and affect controlled-substance compliance obligations under NRS 453/NAC 453 for any entities that may encounter these substances (e.g., healthcare, pharmacy, laboratories, enforcement, and supply chain controls).